![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessEpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205
Expression of epithelial cell adhesion molecule (EpCAM) is deregulated in epithelial malignancies. Beside its role in cell adhesion, EpCAM acts as signalling molecule with tumour-promoting functions. Thus, EpC...
-
Article
Open AccessDistinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer
The TMPRSS2-ERG gene fusion resulting in ERG overexpression has been found in around 50% of prostate cancers (PCa) and is a very early event in tumorigenesis. Most studies have reported on selected surgical cohor...
-
Article
Open AccessInsulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer
Insulin-like growth factor (IGF) and insulin (INS) proteins regulate key cellular functions through a complex interacting multi-component molecular network, known as the IGF/INS axis. We describe how dynamic a...
-
Article
Erratum: Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor
Correction to: Cancer Gene Therapy (2002) 9, 117–125; doi:10.1038/sj.cgt.7700416 The authors have noticed an error in the ‘Materials and methods’ section, where the sequence of the antisense ODNas750/15 target...
-
Article
Open AccessAndrogen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells
Interactions between polypeptide growth factors and the androgen receptor (AR) are important for regulation of cellular events in carcinoma of the prostate. Basic fibroblast growth factor (bFGF), the prototype...
-
Article
Open AccessSwitch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we establish...